Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIN-103 in IBS-D
NCT06153420Phase 2Terminated
- Sponsor
- CinPhloro Pharma
- Start
- Dec 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CIN-103 in Irritable bowel syndrome with diarrhea (IBS-D) (3 arms), sponsored by CinPhloro Pharma. Primary endpoint: Occurrence of meeting Study Composite Responder status for an adult subject with IBS-D at 12 weeks. Started Dec 2023; status: terminated.
02
Drugs
CIN-103
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT06153420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06153420.